HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.

Abstract
In cell culture, the compound 317615.2HCl, a potent inhibitor of VEGF-stimulated HUVEC proliferation, was not very effective against Calu-6 non-small-cell lung carcinoma cells (IC50 26 microM). Exposure to combinations of paclitaxel or carboplatin and 317615.2HCl with Calu-6 cells in culture resulted in cell survival that reflected less-than-additivity to additivity of the two agents. Administration of 317615.2HCl orally twice daily to nude mice bearing subcutaneous Calu-6 tumors resulted in a decreased number of intratumoral vessels as determined by CD31 and CD105 staining to 50% of the number in control tumors. 317615.2HCl showed antitumor activity against the Lewis lung carcinoma and increased the tumor growth delay produced by paclitaxel by 5-fold, that produced by gemcitabine by 2-fold and that produced by carboplatin by 1.7-fold. There was a decrease in the number of lung metastases in the Lewis lung carcinoma that paralleled the increased response of the primary tumor with each treatment combination. Administration of 317615.2HCl also increased the tumor growth delay produced by fractionated radiation therapy in the Lewis lung tumor. Treatment with 317615.2HCl was an effective therapy in the Calu-6 non-small-cell lung carcinoma xenograft when the compound was administered early (days 4-18) or later (days 14-30). Combination treatment regimens in which 317615.2HCl was administered along with or sequentially with paclitaxel or carboplatin were much more effective than the chemotherapeutic agents administered alone. 317615.2HCl is in early clinical testing.
AuthorsB A Teicher, K Menon, E Alvarez, E Galbreath, C Shih, M M Faul
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 48 Issue 6 Pg. 473-80 (Dec 2001) ISSN: 0344-5704 [Print] Germany
PMID11800028 (Publication Type: Journal Article)
Chemical References
  • 317615 x 2HCl
  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Alkylating
  • Enzyme Inhibitors
  • Isoenzymes
  • Organic Chemicals
  • Protein Kinase C
  • Protein Kinase C beta
Topics
  • Administration, Oral
  • Angiogenesis Inhibitors (pharmacology)
  • Animals
  • Antineoplastic Agents, Alkylating (pharmacology)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Isoenzymes (antagonists & inhibitors, pharmacology)
  • Lung Neoplasms (drug therapy, pathology, secondary)
  • Mice
  • Mice, Nude
  • Neoplasms, Experimental
  • Organic Chemicals
  • Protein Kinase C (antagonists & inhibitors, pharmacology)
  • Protein Kinase C beta
  • Rats
  • Rats, Inbred Lew
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: